Apple plans to suspend sales of the Series 9 and Ultra 2 versions of the Apple Watch in the United States this week due to an ongoing patent dispute with the medical technology company, Masimo. The International Trade Commission (ITC) issued a ban on the sale of watch models that feature blood oxygen level measurement functionality. The White House administration has 60 days to review the ITC’s decision, but Apple has decided to suspend sales ahead of time to comply with the order. It is expected that this sales pause will cost Apple approximately $300-400 million during the holiday season. Nevertheless, the impact of this loss on the company’s total revenue, estimated at around $120 billion from October to December, is unlikely. Apple has promised to take all necessary steps to resume the sale of the affected watch models in the United States if the ITC ban is not lifted. The Apple Watch SE model, which does not have blood oxygen level measurement functionality, will still be available for purchase in the USA.
FAQ (Frequently Asked Questions)
The source of the article is from the blog combopop.com.br